Background: Most people require dietary vitamin D to achieve the recommended concentration of 25-hydroxyvitamin D
Introduction
Vitamin D is the generic name for compounds that exhibit the biological activity of cholecalciferol (vitamin D 3 ). Vitamin D is essential for bone health and for regulating blood calcium and phosphate concentrations, but it is also involved in other biological functions such as immunity, cell proliferation, and apoptosis. Cholecalciferol needs 2 hydroxylations to become hormonally active.
In the first hydroxylation, 25-hydroxyvitamin D [25(OH)D]
11 is produced in the liver upon 25-hydroxylase action (cytochrome P450, family 2, subfamily R, member 1); after its transport via the bloodstream to the kidney bound to vitamin D-binding protein, it undergoes another hydroxylation by 1-a-hydroxylase (cytochrome P450 family 27, subfamily B, member 1) to form 1,25-dihydroxyvitamin D (1) . In a recent Mendelian randomization analysis, vitamin D status, which is usually estimated by measuring the plasma 25(OH)D concentration, has been negatively associated with all-cause and cancer mortality (2) . Although a substantial fraction of total body vitamin D is produced in the skin after exposure to UV light, most individuals require at least some dietary vitamin D, either in foods rich in vitamin D (3) or in supplements, to reach the vitamin D-sufficient serum concentration. Cholecalciferol is the main dietary source of vitamin D and is found in large amounts in food items such as milk and dairy products, fatty fish, and cod liver oil. However, previous studies have suggested that dietary vitamin D intakes in several Western countries are below recommended concentrations (current RDA in the United States is 15 mg) (4), and according to NHANES 2005 NHANES -2006 , 37% of the US population uses a dietary supplement containing vitamin D (5) .
It has been assumed that vitamin D uptake is governed by the same intraluminal factors as those that have been described for lipids (6, 7) . These factors include emulsification, solubilization in mixed micelles, and diffusion across the unstirred water layer before uptake by enterocytes. TGs and vitamin D then show marked differences regarding their uptake by intestinal cells (8) . Although it was thought that vitamin D was absorbed via passive diffusion, previous studies have shown that, at least at nutritional doses, intestinal cell membrane proteins are involved in the uptake of vitamin D on the apical side of the enterocyte. These proteins are scavenger receptor class B, type 1; cluster determinant 36; and Niemann-Pick C1-like 1 (9) . This list is likely not complete because it has been suggested that other apical membrane transporters, e.g., the ATP-binding cassette subfamily G, member 5 and 8 heterodimer, might also be involved (7) . After its uptake, cholecalciferol has to reach the basolateral side of the cell to be secreted in the circulation, yet nothing is known about its transport from the apical to the basolateral side of the enterocyte. It has been assumed that most absorbed cholecalciferol is incorporated as such into chylomicrons, which are subsequently secreted into the lymph (apolipoprotein B-dependent route) (10), but it is not known whether a fraction of cholecalciferol is incorporated into HDL secreted by the intestine, as described for cholesterol and vitamin E (11, 12) .
The heritability of blood vitamin D status is ;30% (13), and common variants in cytochrome P450, family 2, subfamily R, member 1 (2, 14-17); group-specific component (GC) (also known as vitamin D-binding protein) (18) ; vitamin D (1,25-dihydroxyvitamin D) receptor (19); 7-dehydrocholesterol reductase (DHCR7) (14, 15, 20) ; and cytochrome P450, family 24, subfamily A, member 1 (14, 15, 19) have been associated with fasting plasma 25(OH)D concentrations. There is also a wide variation in the response of blood 25(OH)D to vitamin D supplementation, and this response has been shown to be partly genetically modulated (2, 16, 17, 19, 21, 22) . Moreover, as stated previously, at least a portion of vitamin D absorption requires protein transport (6, 7, 9, 23) . Several groups have previously shown that genetic variants are associated with the variability in the postprandial chylomicron TG response (24) (25) (26) , and chylomicrons are responsible for the transport of newly absorbed cholecalciferol into the peripheral circulation. Moreover, we have also shown that the variation in the postprandial response to other lipid-soluble micronutrients (i.e., tocopherol, lutein, lycopene, and b-carotene) (27) (28) (29) (30) that share common absorption processes with cholecalciferol was modulated by single-nucleotide polymorphisms (SNPs) in genes involved in both the intestinal transport of these micronutrients and chylomicron metabolism. This set of arguments allows us to suggest that cholecalciferol bioavailability could be at least partly genetically modulated.
The main objectives of this study were to describe the postprandial chylomicron cholecalciferol response to a cholecalciferolrich meal and its interindividual variability and to assess whether the interindividual variability in cholecalciferol bioavailability is associated with genetic variants located in or near candidate genes involved in vitamin D or lipid metabolism.
Methods
Subject number and characteristics. Forty healthy, nonobese, nonsmoking (31) men were recruited for the study (NCT02100774). Subjects reported normal energy consumption (i.e., ;2500 kcal/d), with <2% alcohol as total energy intake. Subjects had no history of chronic disease, hyperlipidemia, or hyperglycemia and were not taking any medications known to affect vitamin D or lipid metabolism the month before the study or during the study period. Because of the relatively large volume of blood collected during the study, a blood hemoglobin concentration >13 g/dL was an inclusion criteria. The study was approved by a regional committee on human experimentation. The procedures followed were in accordance with the Declaration of Helsinki of 1975 as revised in 1983. Objectives and requirements of the study were fully explained to all participants before beginning the study, and written informed consent was obtained from each subject. One subject left the study for personal reasons before he participated in the postprandial experiment, which left 39 subjects whose baseline characteristics are reported in Table 1 .
DNA preparation and genotyping methods. DNA preparation and genotyping methods were performed as previously described (28) . The whole genome was genotyped with the use of HumanOmniExpress BeadChip (Illumina), which allowed for the analysis of ;7.33 3 10 5 SNPs per DNA sample. Subjects were also genotyped for 11 additional SNPs as described in the ''Choice of Candidate Genes'' section (32) .
Postprandial experiments. To assess cholecalciferol bioavailability, we measured the postprandial chylomicron cholecalciferol response to a cholecalciferol-rich meal. This approach is commonly used to experimentally assess fat-soluble vitamin and carotenoid bioavailability (33) (34) (35) (36) . Because it has been shown that season is an important prediction factor for vitamin D response variation (37) , the postprandial experiments were performed over a short period of time, more precisely between September and November. This postprandial experiment was part of a larger clinical research study in which we assessed the bioavailability of other lipid micronutrients and nutrients, i.e., lutein (30) , tocopherol (27) , lycopene (29) , b-carotene (28), and cholesterol (unpublished data), in the same group of subjects. To avoid carryover and/or competition between the studied compounds, a washout period of $2 wk was respected in between 2 test meals. Subjects were asked to refrain from the consumption of vitamin supplements and vitamin D-rich foods 48 h before the postprandial experiment (an exclusion list was provided by a dietitian). In addition, subjects were asked to eat dinner between 1900 and 2000 the day before the postprandial experiment and to abstain from any food or beverage consumption afterward with the exception of water. After the overnight fast, subjects arrived at the local clinic to have their baseline blood sample taken. Subjects then consumed the test meal together with 5 mg supplemental cholecalciferol (2 vials of 100-kIU UVEDOSE; Crinex). The meal also contained 70 g semolina cooked in 200 mL hot water, 40 g white bread, 60 g cooked egg whites, 50 g peanut oil, and 330 mL mineral water. Subjects were asked to consume the meal at a steady pace, with half of the meal consumed in 10 min and the remainder consumed within 30 min (to diminish the variability because of different rates of intake and, thus, gastric emptying).
No other food was permitted during the following 8 h. However, subjects were allowed to drink any remaining water from the meal. Additional blood samples were drawn 2, 3, 4, 5, 6, and 8 h after meal consumption. Blood was collected via evacuated purple-top glass tubes containing potassium EDTA. Tubes were immediately placed on ice and covered with aluminum foil to avoid light exposure. Plasma was isolated by centrifugation (10 min at 4°C and 1620 3 g) <2 h after collection.
Chylomicron preparation. Chylomicrons were prepared from plasma samples as previously described (28) . Immediately after recovery, chylomicrons were stored at 280°C until analysis.
Ability of Caco-2 cells to convert cholecalciferol to 25(OH)D. Caco-2 clone TC7 cells were cultured as previously described (38) . For each experiment, cells were seeded and grown on 6-well plates for 14 d to obtain confluent and highly differentiated cell monolayers. Twelve hours before each experiment, the complete medium was replaced with DMEM supplemented with 1% antibiotics and 1% nonessential amino acids. Cells were then incubated with DMEM supplemented with 1% antibiotics, 1% nonessential amino acids, 1% BSA, and 50 mM cholecalciferol up to 24 h. After incubation, the cell medium was harvested, and the cells were scraped in ice-cold PBS. The samples were then stored at 280°C until analysis.
Vitamin D extraction and analysis by HPLC. Up to 2 mL of the samples were deproteinated by adding 1 volume of ethanol that also contained ergocalciferol (vitamin D 2 ) as an internal standard and vortexed for 30 s. After adding 2 volumes of hexane, the mixture was vortexed for 10 min and centrifuged at 500 3 g for 10 min at 4°C. The upper phase (containing the different vitamin D forms) was collected, and the sample was extracted a second time with hexane following the same procedure. The hexane phases were pooled and completely evaporated under nitrogen gas. The dried residue from the chylomicron samples was dissolved in 200 mL acetonitrile:methanol:water (60:38:2) that contained 20 mM sodium perchlorate and 10 mM perchloric acid, whereas the dried residue from cell samples was dissolved in 200 mL acetonitrile. A volume of 200 mL was used for the HPLC analysis. Cholecalciferol and ergocalciferol from chylomicron samples were separated with the use of a 250 3 4.6-mm reversed-phase C18 5-mm Zorbax column (Interchim) and a guard column and analyzed as previously described (9) .
Cholecalciferol, 25(OH)D, and ergocalciferol from cell samples were separated with the use of a 100 3 3-mm ACE 3 C18-AR column (AIT). The mobile phase consisted of a gradient of acetonitrile and water (pH 10). The flow rate was 0.22 mL/min, and the column temperature was 20°C. The gradient profile of the mobile phase (acetonitrile:water) was set at 60:40 from 0 to 1.5 min. It then changed linearly to 100:0 for 6 min. This ratio was maintained for 12 min before the mobile phase was changed back to 60:40 from 18 to 18.5 min. This last ratio was finally maintained for 11.5 min. Choice of candidate genes. Candidate genes included those for which the encoded protein has previously been shown to be involved in cholecalciferol uptake by the enterocyte in vitro (9) , genes that have been suggested to be involved (directly or indirectly) in the metabolism of fatsoluble micronutrients in the enterocyte (23) , and genes that have been associated with circulating blood 25(OH)D concentration in genome-wide (15, (39) (40) (41) or candidate gene (18, 20, 21, (42) (43) (44) (45) association studies. Consequently, 61 genes were selected (Supplemental Table 1 ), representing 4608 SNPs. In addition, we added 27 SNPs from 14 genes associated with the postprandial chylomicron TG response in the same subjects (24) . Indeed, chylomicrons are the carrier of both newly absorbed TGs and cholecalciferol (10) in the blood. Thus, we hypothesized that the genetic variants that affect the secretion and clearance of chylomicrons also likely affect cholecalciferol response. Finally, we added 11 SNPs that have been previously associated with lipid metabolism and that were not genotyped with BeadChip (Supplemental Table 2 ). After genotyping the subjects, SNPs for which the genotype call rate was <5% or SNPs that presented a significant departure from the Hardy-Weinberg equilibrium (P < 0.05; chisquared test) were excluded from all subsequent analyses. A total of 855 SNPs were excluded, leaving 3791 SNPs for the partial least squares (PLS) regression analysis (Supplemental Figure 1 ).
Calculation and statistical analysis. The trapezoidal approximation method was used to calculate the AUC of the postprandial plasma chylomicron cholecalciferol concentration over 8 h (henceforth referred to as the cholecalciferol response). All data were expressed as means PLS regression. To identify SNPs associated with the variability observed in the cholecalciferol response, we used PLS regression following previously published rationale and model assumptions (24, 30) . Among the 3791 candidate SNPs, PLS identified those that were predictive of the cholecalciferol response according to their variable importance in the projection (VIP) value. A general genetic model was assumed. The 3 genotypes of each SNP (i.e., most frequent homozygote allele, heterozygote, less frequent homozygote allele) were treated as separate categories, with no assumption made about the effect conferred by the variant allele on cholecalciferol response. Different PLS regression models were built with the use of increasing VIP threshold values. The selection of the PLS regression model was carried out as previously shown (29) . Additional validation criteria and procedures of the PLS regression models are described in Supplemental Methods (Supplemental Figures 2 and 3) . SIMCA-P13 software version 13.0.3 (Umetrics) was used for all multivariate data analyses and modeling.
With the knowledge of a subjectÕs genotype at the SNPs associated with the variability observed in the cholecalciferol response, it was possible to calculate the subjectÕs ability to respond to cholecalciferol according to the following equation:
with RP as the responder phenotype (i.e., the cholecalciferol response), a as a constant (equal to the mean cholecalciferol response), b the number of SNPs in the selected PLS regression model, r i the regression coefficient of the i th SNP included in the PLS regression model, and genotype.(SNP i ) as a Boolean variable indicating the subjectÕs genotype at the i th SNP. In a second approach, we performed univariate analyses to compare the cholecalciferol response between subgroups of subjects who bore different genotypes for the SNPs present in the selected PLS model. Differences obtained between the various genotype subgroups were analyzed with the use of a StudentÕs t test with the Benjamini-Hochberg correction with QVALUE software version 1.0 (46) and R software version 3.0.2. For all tests, an adjusted P value <0.05 was considered significant.
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Results Vitamin D status of the subjects. As shown in Table 1 Chylomicron vitamin D responses to the cholecalciferolrich meal. The mean cholecalciferol response after the consumption of the test meal is shown in Figure 1 . In total, 37 of the 39 subjects had cholecalciferol concentrations below our limit of detection in their fasting chylomicron fraction, and the remaining 2 subjects had extremely low cholecalciferol concentrations (0.27 6 0.01 nmol/L). The maximal chylomicron cholecalciferol concentration was obtained 5.4 6 0.3 h after meal intake. Note that the subject with the lowest response exhibited an increase in his chylomicron cholecalciferol concentration only 8 h after meal intake. The individual responses ranked by increasing AUC are shown in Figure 2 . They followed a normal distribution (P > 0.1 after the Kolmogorov-Smirnov and Shapiro-Wilk tests, respectively; skewness = 0.165; kurtosis = 20.394). The CV of the cholecalciferol response was 47%, and the ratio between the highest and lowest responder was ;34. The cholecalciferol response correlated relatively well with the chylomicron TG response (r = 0.60; P < 0.001) and with fasting TG (r = 0.478; P = 0.002). Note that the cholecalciferol response was not related to the vitamin D status of the subjects [as estimated by their fasting plasma 25(OH)D concentrations] (r = 0.04; P > 0.1).
The postprandial chylomicron 25(OH)D concentrations are shown in Figure 3 . These concentrations did not vary significantly over the postprandial period (P > 0.1).
Genetic variants associated with the cholecalciferol response to the cholecalciferol-rich meal. The PLS regression model that included all 3791 candidate SNPs (used as qualitative X variables) in 61 candidate genes (Supplemental Table 1 ) described the cholecalciferol response with good accuracy (R 2 = 0.879) but was not predictive of this response (Q 2 = 20.1; R 2 after cross-validation). Therefore, to improve the model and to find an association of SNPs more predictive of the cholecalciferol response, we filtered out those that displayed the lowest VIP value (i.e., those that made no important contribution to the PLS regression model). After the application of several increasing VIP value thresholds, we selected a model with a VIP threshold value of 2.1 that included 18 SNPs, of which 17 were not in linkage disequilibrium. The 17 SNPs were located in or near 13 genes ( Table  2 ) and described 63.5% of the variance (R The association of the 17 selected SNPs with the cholecalciferol response was further evaluated with the use of univariate statistics by comparing the cholecalciferol response of subjects who bore different genotypes for each SNP (Table 2 ). For 11 of these 17 SNPs, subjects who bore different genotypes exhibited a significantly different cholecalciferol response (adjusted P value <0.05).
Genetic score to calculate the cholecalciferol response of a genotyped subject. With the knowledge of a subjectÕs genotype at the 17 aforementioned loci, it was possible to calculate the subjectÕs ability to respond to cholecalciferol according to Equation 1 with a = 114.18 and b = 17. A list of regression coefficients calculated by SIMCA-P13 can be found in Supplemental Table 4 . 
Discussion
To our knowledge, this study is only the second report of the chylomicron cholecalciferol response to a cholecalciferol-rich meal in humans (48) . The increased subject number and longer duration of time points taken postprandially provide a more complete picture of cholecalciferol bioavailability in humans than previous work.
The subjects enrolled in our study were apparently healthy. However, most presented subdeficient vitamin D concentrations, as classified by a fasting plasma 25(OH)D concentration <75 nmol/L (47). This observation was not surprising because the prevalence of vitamin D insufficiency is high in France, as it is elsewhere (49, 50) .
The first major observation of this study was that the interindividual variability in cholecalciferol bioavailability was quite large, with a 34-fold difference in the AUC observed between the highest and lowest cholecalciferol responders. The lack of a significant correlation between the chylomicron cholecalciferol response and fasting plasma 25(OH)D concentration in our subjects could suggest that the variability in cholecalciferol bioavailability does not significantly affect long-term vitamin D status in these individuals. This is perhaps because of the fact that the fasting plasma 25(OH)D concentration is the result of interactions between several factors, including vitamin D synthesis by the skin, dietary vitamin D intake, vitamin D absorption efficiency, hepatic vitamin D metabolism to 25(OH)D, and rates of renal conversion to 1,25-dihydroxyvitamin D.
To identify genetic variants that are associated with the interindividual variability in the chylomicron cholecalciferol response, we employed a statistical approach that previously allowed us to identify combinations of candidate SNPs involved in the variability of the postprandial chylomicron response to other fat-soluble vitamins (i.e., vitamins E and A) (27, 28) . This approach revealed that 63.5% of the interindividual variability in the postprandial cholecalciferol response was explained by 17 SNPs in or near 13 genes. Five of these genes (ATP-binding cassette, subfamily A, member 1; apolipoprotein B; blocked early in transport 1 homolog; lipoprotein lipase; and N-acetyltransferase 2) have been associated with the postprandial chylomicron TG response in the same group of subjects (24) . Because it has been assumed that most newly absorbed cholecalciferol is carried from the intestine to peripheral organs and the liver via chylomicrons (48) , it is plausible that SNPs in these genes have an indirect effect on the cholecalciferol response by modulating chylomicron metabolism. Indeed, 3 of these SNPs (blocked early in transport 1 homolog reference SNP rs10464587, lipoprotein lipase rs10096561, and N-acetyltransferase 2 rs4921920) values. Note that ABCB1 rs2235015 and ABCB1 rs10260862 were in linkage disequilibrium. We kept one, chosen at random (ABCB1 rs10260862), in the final selected partial least squares regression model and removed the other because it provided redundant information. 4 The given biological role of the protein is that in relation to vitamin D bioavailability. Cholecalciferol bioavailability characterization 2425
have been previously associated with the variability in the postprandial chylomicron TG response in the same group of subjects (24) . This is further illustrated by the significant correlation between the cholecalciferol and chylomicron TG responses. However, this correlation was only partial, highlighting the fact that a significant considerable part of the variance of the cholecalciferol response can be attributed to factors other than the variance in the chylomicron TG response, such as processes specific to cholecalciferol metabolism. Indeed, several SNPs associated with the interindividual variability in the cholecalciferol response were located in genes involved more directly in vitamin D metabolism and transport. Intestine-specific homeobox is an intestinal transcription factor that modulates scavenger receptor class B, member 1 (SCARB1) expression (51) . SCARB1 encodes scavenger receptor class B, type 1, an apical membrane protein that is involved in cholecalciferol uptake by enterocytes (9) . In addition, an SNP in SCARB1 was significantly associated with the cholecalciferol response in our PLS regression model. Solute carrier family 10 (sodium/bile acid cotransporter), member 2 encodes for the apical sodium-dependent bile acid transporter (ASBT), the main transporter involved in bile acid uptake in the distal ileum (52) and a candidate transporter for cholecalciferol uptake. Indeed, data from our laboratory suggest that ASBT is involved in the cellular uptake of cholecalciferol by Caco-2 TC7 cells and by ASBT-transfected cells (data not shown). GC encodes for vitamin D-binding protein, which is responsible for the plasma transport of 25(OH)D, and several SNPs in this gene have been associated with plasma 25(OH)D concentration (20, 53) . The association of an SNP in GC with the variability in cholecalciferol bioavailability could suggest the existence of a feedback loop that regulates the circulating 25(OH)D concentration. ATP-binding cassette, subfamily B, member 1 encodes for P-glycoprotein (also known as multidrug resistance protein 1), which is involved in the efflux of xenobiotic compounds with a broad substrate specificity. Unpublished data from our lab that have shown that ABCB1-transfected cells effluxed more cholecalciferol than control cells further support that this apical membrane protein could also be involved in cholecalciferol efflux. The association of 2 SNPs in pancreatic lipase with the cholecalciferol response suggests that the hydrolysis efficiency of dietary TGs, in which cholecalciferol is assumed to be solubilized, is an important factor regarding cholecalciferol absorption efficiency. This could be because of either the fact that pancreatic lipase allows the release of cholecalciferol from TGs and its incorporation in micelles or that the lipolysis products of TGs by pancreatic lipase, i.e., FAs, facilitate cholecalciferol absorption (38) . In support of this hypothesis, it has been shown that patients with cystic fibrosis with pancreatic insufficiency display lower cholecalciferol absorption (54) . Finally, we observed the association of an SNP in DHCR7 with cholecalciferol bioavailability.
DHCR7 encodes for 7-dehydrocholesterol reductase, an enzyme that catalyzes the conversion of 7-dehydrocholesterol to cholesterol. 7-Dehydrocholesterol also serves as a precursor of cholecalciferol in keratinocytes upon UVB exposure (55) . It could be hypothesized that the increased activity of DHCR7 would reduce the pool of 7-dehydrocholesterol available for cholecalciferol synthesis after sun exposure, inducing in turn an upregulation in cholecalciferol bioavailability to maintain homeostatic concentrations. This hypothesis is further supported by the fact that DHCR7 variants have been previously associated with plasma 25(OH)D concentrations (2, 14, 15, 20) , although future studies are required to test this hypothesis.
25(OH)D was observed in the chylomicron-containing fraction of blood sampled during the postprandial period. This measurement was carried out to assess whether a fraction of ingested cholecalciferol was immediately metabolized to 25(OH)D in the enterocyte and then packaged into the chylomicrons. Indeed, although it is well known that the liver is the main organ that converts cholecalciferol to 25(OH)D, there is no clinical data to our knowledge regarding the possibility that the intestine can convert a substantial fraction of newly absorbed cholecalciferol to 25(OH)D and incorporate it into chylomicrons. However, it has been shown that the human intestinal Caco-2 cells possess 25-hydroxylase activity (56) , suggesting that the intestinal cell can convert a fraction of newly absorbed cholecalciferol to 25(OH)D. Furthermore, it is possible that, if newly absorbed cholecalciferol is converted to 25(OH)D in the intestine, it is directly transported to the liver via the portal vein, as has been reported in rats (57) . In our study, the fact that 25(OH)D concentration did not significantly vary in the chylomicron fraction during the postprandial period-together with the fact that our complementary experiment in Caco-2 showed that the fraction of cholecalciferol converted to 25(OH)D in the intestinal cell was very low (i.e., 2.3%) and even nondetectable when cholecalciferol was provided to the Caco-2 monolayers in the micelles that contained cholesterol (data not shown)-suggests that the 25(OH)D recovered in the chylomicron fraction did not come from the cholecalciferol ingested by the subjects. 25(OH)D in the chylomicron fraction most likely resulted from the presence of plasma 25(OH)D, i.e., 25(OH)D associated to vitamin D-binding protein, in the TG-rich lipoprotein fraction isolated from the blood.
To conclude, the results from this study have allowed us to describe the interindividual variability in cholecalciferol bioavailability. They also suggest for the first time to our knowledge that this variability is at least partly explained by a combination of SNPs in genes involved in cholecalciferol and chylomicron metabolism and that ASBT and ABCB1 are involved in cholecalciferol bioavailability, likely in its intestinal uptake. We acknowledge some limitations of the study. It is likely that SNPs that have a significant effect on cholecalciferol bioavailability were not entered in the PLS regression analysis because they were not present on the BeadChip, they were excluded from the analysis (for not following the Hardy-Weinberg equilibrium), or simply because they were not located in the candidate genes. Moreover, these findings need to be tested in other population groups (e.g., based on sex, age, or genetic backgrounds). Thus, future studies are required to confirm these associations and to identify other genes and/or SNPs involved in cholecalciferol bioavailability.
